2023
HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma
Coleman N, Marcelo K, Hopkins J, Khan N, Du R, Hong L, Park E, Balsara B, Leoni M, Pickering C, Myers J, Heymach J, Albacker L, Hong D, Gillison M, Le X. HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma. JCO Precision Oncology 2023, 7: e2200211. PMID: 36603172, PMCID: PMC9928766, DOI: 10.1200/po.22.00211.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaMD Anderson Cancer CenterSquamous cell carcinomaAnderson Cancer CenterCo-occurring mutationsClinical courseSurvival outcomesCancer CenterCell carcinomaShorter disease-free survivalPoor clinic outcomePrimary definitive treatmentTherapeutic combination strategiesDisease-free survivalPoor clinical outcomePatient demographic informationImproved OSDefinitive treatmentMedian ageOverall survivalFoundation MedicineMale patientsClinical outcomesClinic outcomesTreatment response
2019
Variations in HPV function are associated with survival in squamous cell carcinoma
Gleber-Netto FO, Rao X, Guo T, Xi Y, Gao M, Shen L, Erikson K, Kalu NN, Ren S, Xu G, Fisch KM, Akagi K, Seiwert T, Gillison M, Frederick MJ, Johnson FM, Wang J, Myers JN, Califano J, Skinner HD, Pickering CR. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight 2019, 4: e124762. PMID: 30626753, PMCID: PMC6485353, DOI: 10.1172/jci.insight.124762.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaSquamous cell carcinomaCell carcinomaTreatment responseLong-term survival ratesHPV-related cancersRadiotherapy-related morbiditySubset of patientsPoor treatment responseNew therapeutic approachesSubset of tumorsPrognostic biomarker signaturesTreatment deintensificationHPV positivityOPSCC patientsHPV- tumorsStandard therapyPoor outcomeCervical carcinomaClinical similaritiesHPV biologyTherapeutic approachesIndependent cohortPatient stratificationSurvival rate